# AlphaGenome Analysis Query Plan — Johnny's ASPS

**Patient:** Johnny
**Diagnosis:** Alveolar Soft Part Sarcoma (ASPS)
**Somatic Alterations:**
- DNMT1 Gene Translocation: t(1;19)(p35.2;p13.2)(chr1:g.31048832::chr19:g.10270729) — exon 14
- ASPSCR1-TFE3 Gene Translocation: t(17;X)(q25.3;p11.23)(chr17:g.79958053::chrX:g.48895821) — ASPSCR1 exon 7 to TFE3 exon 4

**Current Treatment:**
- Doxycycline (50 days)
- Cimetidine (21 days)
- Hydroxychloroquine (19 days)

---

## Query 1: Full Somatic Alteration Mapping & Analysis

Map and analyze the somatic alterations. For each translocation individually and then combined:
- Top tumor strengths, vulnerabilities, and druggable values
- "Hidden giants" — overlooked but critical pathway impacts
- Metabolic trap assessment given tumor weaknesses
- Reverse Warburg analysis
- Combined synergistic effects on tumor and microenvironment

**Data sources:** AlphaGenome ISM, multi-modal chromatin, gene expression predictions

---

## Query 2: Current Blockade Evaluation & Escape Routes

Evaluate the strength of the current triple blockade against the tumor:
- Doxycycline (50 days) — MMP inhibition + mitochondrial disruption
- Cimetidine (21 days) — histamine/angiogenesis blockade
- Hydroxychloroquine (19 days) — autophagy/lysosomal disruption

Present against relevant vulnerability scores and druggable pathways. Identify potential escape routes with probability assessments.

**Data sources:** Drug target expression data, ISM vulnerability scores

---

## Query 3: Conceptual Functional Impact Analysis (Top 50x3)

Comprehensive biological analysis of both translocations:
- Functional impact on gene function, protein structure, regulatory pathways
- Hidden giants and metabolic implications (metabolic trap, reverse Warburg)
- Escape route identification with qualitative likelihood

**Deliverables:**
- Top 50 strengths (ranked)
- Top 50 vulnerabilities (ranked)
- Top 50 druggable values (ranked)
- Calculated individually per translocation, then combined synergistic effects

**Note:** Synthesize with emphasis on conceptual nature where AlphaGenome data has limitations

---

## Query 4: Top 5 Highest Impact Tracks per Translocation

For each chromosome translocation variant:
- Calculate maximum absolute change for each track
- Rank top 5 highest impact tracks (1st through 5th)
- Display metadata: biosample name, tissue type, specific assay
- Impact scores
- Biological context summary — which cell types/tissues are most sensitive

**Data sources:** AlphaGenome variant scoring, ISM results

---

## Query 5: War Game Simulation — Translocation Interactions + Treatment

Simulate how ASPSCR1-TFE3 fusion and DNMT1 translocations interact within the same cell:
- Individual translocation impacts
- Combined cellular outcomes
- Treatment blockade overlay (Doxycycline 50d, Cimetidine 21d, HCQ 19d)
- Assumption: treatment continues

**Approach:** Analyze individual impacts, predict combined outcomes, model treatment interference

---

## Query 6: Sequential Priming Model — 30d Doxy then 90d Triple

Simulate treatment model:
- Phase 1: 30 days Doxycycline alone (priming)
- Phase 2: Add Cimetidine + Hydroxychloroquine for 90 days (full blockade)

Model the sequential impact on tumor biology.

---

## Query 7: Tumor Cell Death Timeline Chart

Create a chart showing over a 90-day period:
- Tumor cell death curve with sequential Doxycycline priming
- Fibroblast "melting" overlay (stromal collapse)
- Key inflection points

---

## Query 8: Immune System Deep Dive + DNMT1 Mutation Probability

Analyze:
- Is the immune system scoring as highly active?
- Cimetidine impact on Treg shield (histamine pathway)
- Doxycycline mitochondrial impact on Tregs
- Given active immune attack: probability of DNMT1 driving a mutation in the translocated cancer cell
- Re-simulate the treatment timeline with these immune considerations

---

## Query 9: Treatment Comparison Simulation

Compare two treatment approaches:

**Approach A (Current):** Triple blockade — Doxycycline + Cimetidine + HCQ (continuous)

**Approach B (Immunotherapy Combo):**
- Months 1-3: Nivolumab + Cabozantinib + Ipilimumab
- Months 4-8: Nivolumab + Cabozantinib only
- Months 9-15: Nivolumab + Cabozantinib + Ipilimumab (restart)

Compare effectiveness, side effect profiles, and impact on cancer biology.

---

## Execution Order

| Priority | Query | Status | Dependencies |
|----------|-------|--------|-------------|
| 1 | Query 1 | **Complete** | Base data (available) |
| 2 | Query 4 | **Complete** | Base data (available) |
| 3 | Query 2 | **Complete** | Query 1 findings |
| 4 | Query 3 | **Complete** | Queries 1+2 findings |
| 5 | Query 5 | **Complete** | Queries 1-4 findings |
| 6 | Query 6 | **Complete** | Query 5 model |
| 7 | Query 7 | **Complete** | Query 6 model |
| 8 | Query 8 | **Complete** | Queries 5-7 |
| 9 | Query 9 | **Complete** | All prior queries |
